Common Contracts
4 similar Warrant Exercise Agreement contracts by Can-Fite BioPharma Ltd., ReWalk Robotics Ltd., Stellar Biotechnologies, Inc.
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • December 23rd, 2021 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of December 20, 2021, is by and between Can-Fite BioPharma Ltd., an Israeli company (the “Company”), and the undersigned holder (each, a “Holder” and, collectively, the “Holders”) of Series A warrants to purchase ordinary shares of the Company, par value NIS 0.25 per share (the “Ordinary Shares”), represented by American Depositary Shares issued by the Company, which warrants were issued on August 16, 2021 and are exercisable at an exercise price of $2.00 per ADS, (the “Original Warrants”).
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • January 10th, 2020 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of January 9, 2020, is by and between Can-Fite BioPharma Ltd., an Israeli company (the “Company”), and the undersigned holder (each, a “Holder” and, collectively, the “Holders”) of warrants to purchase ordinary shares of the Company, par value NIS 0.25 per share (the “Ordinary Shares”), represented by American Depositary Shares issued by the Company, which warrants were issued in September 2015, October 2015, March 2018, January 2019 and April 2019 and are exercisable at an exercise price of $78.75 per ADS, $78.75 per ADS, $30.00 per ADS, $19.50 per ADS and $12.90 per ADS, respectively (the “Original Warrants”).
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • June 11th, 2019 • ReWalk Robotics Ltd. • Orthopedic, prosthetic & surgical appliances & supplies
This Warrant Exercise Agreement (this “Agreement”), dated as of June 5, 2019, is by and between ReWalk Robotics Ltd., an Israeli company (the “Company”), and the undersigned holder (each, a “Holder” and, collectively, the “Holders”) of warrants to purchase ordinary shares of the Company, NIS 0.25 par value per share (the “Ordinary Shares”), issued by the Company, which warrants are exercisable at an exercise price of $7.50 per share (the “Original Warrants”).
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • May 30th, 2018 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of May 24, 2018, is by and between Stellar Biotechnologies, Inc., a British Columbia corporation (the “Company”), and the undersigned holder (each, a “Holder” and, collectively, the “Holders”) of warrants to purchase shares of the Company’s common stock, no par value per share (the “Common Stock”), issued by the Company, which warrants are exercisable at an exercise price of $2.65 per share (the “Original Warrants”).
